SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

2/10/23 9:08:40 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PRLD alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 PRELUDE THERAPEUTICS INC COMMON STOCK Cusip #74065P101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #74065P101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,878,534 Item 6: 0 Item 7: 4,878,551 Item 8: 0 Item 9: 4,878,551 Item 11: 10.193% Item 12: HC Cusip #74065P101 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 4,878,551 Item 8: 0 Item 9: 4,878,551 Item 11: 10.193% Item 12: IN Item 1(a). Name of Issuer: PRELUDE THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 200 POWDER MILL ROAD WILMINGTON, DE 19803 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 74065P101 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 4,878,551 (b) Percent of Class: 10.193% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 4,878,551 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of PRELUDE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of PRELUDE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of PRELUDE THERAPEUTICS INC at January 31, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January, 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $PRLD alert in real time by email

Recent Analyst Ratings for

$PRLD

Date	Price Target	Rating	Analyst
9/19/2024	$5.00	Neutral → Buy	H.C. Wainwright
6/20/2024	$3.00	Equal Weight → Underweight	Barclays
3/13/2024	$7.00	Mkt Outperform	JMP Securities
2/20/2024	$5.00	Buy → Neutral	H.C. Wainwright
12/19/2023	$10.00 → $4.00	Equal-Weight → Underweight	Morgan Stanley
11/21/2022	$8.00 → $6.00	Neutral → Underperform	BofA Securities
9/9/2022	$19.00 → $11.00	Overweight → Equal-Weight	Morgan Stanley
7/29/2022	$9.00	Buy	Jefferies

More analyst ratings

SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

2/10/23 9:08:40 AM ET

$PRLD

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PRLD alert in real time by email

Recent Analyst Ratings for

$PRLD

Date	Price Target	Rating	Analyst
9/19/2024	$5.00	Neutral → Buy	H.C. Wainwright
6/20/2024	$3.00	Equal Weight → Underweight	Barclays
3/13/2024	$7.00	Mkt Outperform	JMP Securities
2/20/2024	$5.00	Buy → Neutral	H.C. Wainwright
12/19/2023	$10.00 → $4.00	Equal-Weight → Underweight	Morgan Stanley
11/21/2022	$8.00 → $6.00	Neutral → Underperform	BofA Securities
9/9/2022	$19.00 → $11.00	Overweight → Equal-Weight	Morgan Stanley
7/29/2022	$9.00	Buy	Jefferies

More analyst ratings

SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $PRLD

SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $PRLD

$PRLD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Baker Bros. Advisors Lp

SEC Form 3 filed by new insider Scherer Paul C

SEC Form 4 filed by Director Sandor Victor

$PRLD Press Releases

Fastest customizable press release news feed in the world

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

$PRLD SEC Filings

Amendment: SEC Form SCHEDULE 13D/A filed by Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

Amendment: SEC Form SCHEDULE 13G/A filed by Prelude Therapeutics Incorporated

$PRLD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Prelude Therapeutics upgraded by H.C. Wainwright with a new price target

Prelude Therapeutics downgraded by Barclays with a new price target

JMP Securities initiated coverage on Prelude Therapeutics with a new price target

$PRLD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Chemistry Officer Combs Andrew bought $69,250 worth of shares (100,000 units at $0.69), increasing direct ownership by 26% to 480,123 units (SEC Form 4)

CEO Vaddi Krishna bought $467,438 worth of shares (675,000 units at $0.69), increasing direct ownership by 51% to 1,999,296 units (SEC Form 4)

CEO Vaddi Krishna bought $14,909 worth of shares (20,416 units at $0.73), increasing direct ownership by 2% to 1,324,296 units (SEC Form 4)

$PRLD Leadership Updates

Live Leadership Updates

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Prelude Therapeutics Reports Full Year 2021 Financial Results

Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

$PRLD Financials

Live finance-specific insights

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

$PRLD Large Ownership Changes

This live feed shows all institutional transactions in real time.